Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
HRHarmony Biosciences Holdings, Inc. logo

Harmony Biosciences Holdings, Inc. (HRMY)

NASDAQ Global Market · Currency in USD
$36.13 ▲ +0.10 (+0.28%)
At close: Oct 23, 4:00 PM ET. Market closed.
$36.13 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$36.03
Open
$36.11
Day's Range
$35.00 – $37.05
52 Week Range
$25.90 – $43.49
Volume
2,313,563
Avg. Volume
903,898
Market Cap
$2.10B
Beta (5Y Monthly)
1.01
PE Ratio (TTM)
11.54
EPS (TTM)
$3.13
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$49.00

Profile: Harmony Biosciences Holdings, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
293
CEO
Jeffrey Dayno

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate $1.11 · Revenue est. $274.03M
DateEst.Actual
Aug 4, 2026$0.96$1.28Beat
May 7, 2026$0.76$0.55Miss
Feb 24, 2026$0.84$0.38Miss
Nov 4, 2025$0.92$0.87Miss
Aug 5, 2025$0.78$0.68Miss
May 6, 2025$0.59$0.78Beat

Analyst view

Consensus price target
$49.00 ▲ +35.6%
Range $34.00 – $70.00
Rating: Buy
Buy 62% · Hold 23% · Sell 15%

Get free alerts on HRMY and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.